| Income Statement | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Gain/loss of issuance | - | 0 | ||
| Debt discount amortization and issuance of warrants | - | 0 | ||
| Total other income (expenses) | 213,279 | 259,516 | ||
| Net loss before provision for income taxes | -282,726 | 35,437 | ||
| Provision for income taxes | - | 0 | ||
| Net loss | -282,726 | 35,437 | ||
| Net loss attributable to the non-controlling interest | - | 0 | ||
| Net loss attributable to bioxytran | -282,726 | 35,437 | ||
| Earning per common share, basic | 0 | 0 | ||
| Earning per common share, diluted | 0 | 0 | ||
| Weighted average number of common shares out-standing, basic | 88,992,242 | 88,839,723 | ||
| Weighted average number of common shares out-standing, diluted | 88,992,242 | 88,839,723 | ||
BIOXYTRAN, INC (BIXT)
BIOXYTRAN, INC (BIXT)